TY - JOUR
T1 - Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chloniakiem z komórek plaszcza - Wyniki miedzynarodowego, wieloosrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore
AU - Jurczak, Wojciech
AU - Rule, Simon
AU - Martin, Peter
AU - Auer, Rebecca
AU - Kahl, Brad S.
AU - Giza, Agnieszka
AU - Jachimczak, Bozena
AU - Advani, Ranjana H.
AU - Romaguera, Jorge
AU - Williams, Michael
AU - Barrientos, Jacqueline
AU - Chmielowska, Ewa
AU - Radford, John
AU - Stilgenbauer, Stephan
AU - McGreivy, Jesse
AU - Clow, Fong
AU - Beaupre, Darrin M.
AU - Kunkel, Lori
AU - Goy, Andre
AU - Blum, Kristie A.
AU - Jedrzejczak, Wiktor
AU - Wang, Michael L.
PY - 2013
Y1 - 2013
N2 - Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling essential for normal B-cell development. Ibrutinib is an oral BTK inhibitor that induces apoptosis and inhibits migration and adhesion of malignant B-cells. Updated results of this international, multicenter, phase 2 study of single agent ibrutinib in relapsed or refractory MCL will be presented. Ibrutinib 560 mg PO QD was administered continuously until disease progression. Tumor response was assessed every 2 cycles (one cycle = 28 days). The study enrolled 115 patients (65 bortezomib-naïve, 50 bortezomib-exposed); 111 patients were treated; 110 were evaluable for response. Baseline characteristics included: median age 68 years, time since diagnosis 42 months, number of prior treatments 3; bulky disease (<10 cm) 13%, prior stem cell transplant 10%, high risk MIPI 49%. Median time on treatment was 9.2 months; 53% of patients remain on therapy. Median PFS was 13.9 months and DOR has not yet been reached. Responses increased with longer treatment: comparing to previous data described at ASH 2011, the CR rate increased from 16% to 39%, and the ORR increased from 69% to 75%.
AB - Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling essential for normal B-cell development. Ibrutinib is an oral BTK inhibitor that induces apoptosis and inhibits migration and adhesion of malignant B-cells. Updated results of this international, multicenter, phase 2 study of single agent ibrutinib in relapsed or refractory MCL will be presented. Ibrutinib 560 mg PO QD was administered continuously until disease progression. Tumor response was assessed every 2 cycles (one cycle = 28 days). The study enrolled 115 patients (65 bortezomib-naïve, 50 bortezomib-exposed); 111 patients were treated; 110 were evaluable for response. Baseline characteristics included: median age 68 years, time since diagnosis 42 months, number of prior treatments 3; bulky disease (<10 cm) 13%, prior stem cell transplant 10%, high risk MIPI 49%. Median time on treatment was 9.2 months; 53% of patients remain on therapy. Median PFS was 13.9 months and DOR has not yet been reached. Responses increased with longer treatment: comparing to previous data described at ASH 2011, the CR rate increased from 16% to 39%, and the ORR increased from 69% to 75%.
KW - Bruton kinase
KW - Ibrutynib
KW - Mantle cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84888639037&partnerID=8YFLogxK
U2 - 10.1016/j.achaem.2013.07.013
DO - 10.1016/j.achaem.2013.07.013
M3 - Article
AN - SCOPUS:84888639037
SN - 0001-5814
VL - 44
SP - 314
EP - 318
JO - Acta haematologica Polonica
JF - Acta haematologica Polonica
IS - 3
ER -